CN Mobile Logo

Search form


Hematologic Malignancies

Hematologic Malignancies

Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.

Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.

During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.

Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma.

The final, long-term analysis of the landmark IRIS study showed that imatinib’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.

Establishing a multidisciplinary oral chemotherapy clinic in a community hospital is feasible and could help reduce emergency department visits, recognize adverse events earlier, and improve staff and patient satisfaction.

The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.